<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Precursor <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> blasts may be positive for CD20 in up to 50% of cases </plain></SENT>
<SENT sid="1" pm="."><plain>There are few reports on the use of the anti CD20 monoclonal antibody, rituximab, in children with <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>We report on two adult patients with precursor <z:e sem="disease" ids="C0023435" disease_type="Neoplastic Process" abbrv="">B-ALL</z:e> who developed significant hepatic toxicity during induction chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Single agent rituximab was given until recovery of liver enzymes was established </plain></SENT>
<SENT sid="4" pm="."><plain>Both patients were able to continue further chemotherapy, underwent an Allo BMT and are now 10-12 months after diagnosis in a continuous CR </plain></SENT>
</text></document>